Diltiazem suit
Executive Summary
Marion Merrell Dow and Rhone-Poulenc Rorer settle a suit filed by MMD alleging that RPR was inappropriately implying generic substitutability of its Dilacor XR for Cardizem CD. RPR had planned a countersuit claiming that MMD was inappropriately implying that Dilacor XR was not as bioavailable as Cardizem CD. Under terms of the agreement, announced Aug. 5, RPR has acknowledged that Dilacor XR is not generically substitutable for Cardizem CD and Marion has acknowledged that the two products "offer similar bioavailability and that both products are safe and effective antihypertensive agents".